ARQT vs DXCM
Arcutis Biotherapeutics, Inc. vs Dexcom — AI-powered side-by-side comparison
ARQT
Arcutis Biotherapeutics, Inc.
66
Buy
VS
| Metric | ARQT | DXCM |
|---|
| AI Score |
66
|
65
|
| Price |
$24.85
|
$89.16
|
| P/E Ratio |
112.23×
|
35.16×
|
| ROE |
-8.5%
|
30.5%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
91.1%
|
62.5%
|
| Debt / Equity |
0.52×
|
0.53×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
33.0
|
65.4
|
| Beta |
1.526
|
1.41
|
| Expected Upside |
+2.6%
|
+2.3%
|
AI Committee View
Current Innellis committee reasoning for ARQT versus DXCM.
ARQT leads by 1 points.
ARQT scores 66/100 (Buy) versus DXCM at 65/100 (Buy).
ARQT Committee View
67% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- ROE of 15.0% shows genuine earnings power backing the valuation — Value
- Revenue growing 76.1% YoY -- genuine top-line momentum — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
Bear Case
- P/E of 113.9 is expensive by classic value standards — Value
- Price-to-book of 18.8x prices in significant intangible value — Value
- MACD histogram negative -- bearish momentum — Technical
DXCM Committee View
67% agreement
6 analysts
The primary driver is eps growing 79.4% yoy. The main limiting factor is p/e of 34.5 is moderate-to-rich. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 36.2% shows genuine earnings power backing the valuation — Value
- EPS growing 79.4% YoY — Growth
- 5 consecutive earnings beats -- consistent execution — Growth
Bear Case
- P/E of 34.5 is moderate-to-rich — Value
- Price-to-book of 9.4x prices in significant intangible value — Value
- Weekly RSI at 75 -- overbought on the larger timeframe too — Technical